Ethanol sclerotherapy or polidocanol sclerotherapy for symptomatic hepatic cysts

類似資料

• Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial
  著者:: Wijnands, Titus FM, 等
  出版事項: (2015)
• Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts
  著者:: Neijenhuis, Myrte K., 等
  出版事項: (2018)
• Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease
  著者:: Gevers, Tom JG, 等
  出版事項: (2012)
• Predictors of treatment response following aspiration sclerotherapy of hepatic cysts: an international pooled analysis of individual patient data
  著者:: Wijnands, Titus F. M., 等
  出版事項: (2016)
• Pasireotide does not improve efficacy of aspiration sclerotherapy in patients with large hepatic cysts, a randomized controlled trial
  著者:: Wijnands, Titus F. M., 等
  出版事項: (2018)